Literature DB >> 21508802

Downregulation of CD38 activation markers by atorvastatin in HIV patients with undetectable viral load.

Stéphane De Wit1, Marc Delforge, Coca Valentina Necsoi, Nathan Clumeck.   

Abstract

Immune activation and chronic inflammation are recognized as major component of HIV disease even in patients with undetectable viral load. We evaluated the effect of atorvastatin on CD38 activation in such patients, in a case-control study (133 cases - 266 controls). At week 48, CD38 activation was significantly lower in cases vs. controls, with no difference in high-sensitivity C-reactive protein (hsCRP) and CD4. These results suggest that atorvastatin reduces the level of immune activation in patients with undetectable viral load.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21508802     DOI： 10.1097/QAD.0b013e328347c083

Source DB:  PubMed          Journal:  AIDS        ISSN： 0269-9370            Impact factor:   4.177


  20 in total

Review 1.  Serious Non-AIDS Events: Therapeutic Targets of Immune Activation and Chronic Inflammation in HIV Infection.

Authors:  Denise C Hsu; Irini Sereti
Journal:  Drugs       Date:  2016-04       Impact factor: 9.546

2.  Rationale and design of the Mechanistic Substudy of the Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE): Effects of pitavastatin on coronary artery disease and inflammatory biomarkers.

Authors:  Udo Hoffmann; Michael T Lu; Devvora Olalere; Elizabeth C Adami; Michael T Osborne; Alex Ivanov; John Sukumar Aluru; Saeyun Lee; Nadja Arifovic; Edgar Turner Overton; Carl J Fichtenbaum; Judith A Aberg; Beverly Alston-Smith; Karin L Klingman; Myron Waclawiw; Tricia H Burdo; Kenneth C Williams; Markella V Zanni; Patrice Desvigne-Nickens; Katharine Cooper-Arnold; Kathleen V Fitch; Heather Ribaudo; Pamela S Douglas; Steven K Grinspoon
Journal:  Am Heart J       Date:  2019-03-04       Impact factor: 4.749

3.  Effects of 96 Weeks of Rosuvastatin on Bone, Muscle, and Fat in HIV-Infected Adults on Effective Antiretroviral Therapy.

Authors:  Kristine M Erlandson; Ying Jiang; Sara M Debanne; Grace A McComsey
Journal:  AIDS Res Hum Retroviruses       Date:  2015-11-16       Impact factor: 2.205

Review 4.  Inflammatory co-morbidities in HIV+ individuals: learning lessons from healthy ageing.

Authors:  Anna C Hearps; Genevieve E Martin; Reena Rajasuriar; Suzanne M Crowe
Journal:  Curr HIV/AIDS Rep       Date:  2014-03       Impact factor: 5.071

Review 5.  The role of statins in the setting of HIV infection.

Authors:  Allison Ross Eckard; Grace A McComsey
Journal:  Curr HIV/AIDS Rep       Date:  2015-09       Impact factor: 5.071

6.  Persistent immune activation in chronic HIV infection: do any interventions work?

Authors:  Reena Rajasuriar; Gabriela Khoury; Adeeba Kamarulzaman; Martyn A French; Paul U Cameron; Sharon R Lewin
Journal:  AIDS       Date:  2013-05-15       Impact factor: 4.177

Review 7.  Understanding and controlling chronic immune activation in the HIV-infected patients suppressed on combination antiretroviral therapy.

Authors:  Babafemi Taiwo; Luis Barcena; Randall Tressler
Journal:  Curr HIV/AIDS Rep       Date:  2013-03       Impact factor: 5.071

Review 8.  Statins to improve cardiovascular outcomes in treated HIV infection.

Authors:  Chris T Longenecker; Allison R Eckard; Grace A McComsey
Journal:  Curr Opin Infect Dis       Date:  2016-02       Impact factor: 4.915

Review 9.  Immune activation and cardiovascular disease in chronic HIV infection.

Authors:  Chris T Longenecker; Claire Sullivan; Jason V Baker
Journal:  Curr Opin HIV AIDS       Date:  2016-03       Impact factor: 4.283

10.  Statin modulation of monocyte phenotype and function: implications for HIV-1-associated neurocognitive disorders.

Authors:  Anjana Yadav; Michael R Betts; Ronald G Collman
Journal:  J Neurovirol       Date:  2016-03-28       Impact factor: 2.643
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.